Chi-Med covers $100m Nasdaq IPO as leads target US
Hutchison China MediTech’s (Chi-Med) $100m IPO on the Nasdaq was oversubscribed three days into bookbuilding, even as bankers pinned their hopes on a select group of US funds.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: